Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Work In Process (2023 - 2025)

Historic Work In Process for Cytosorbents (CTSO) over the last 3 years, with Q3 2025 value amounting to $1.1 million.

  • Cytosorbents' Work In Process changed N/A to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $503000.0 for FY2024, which is 4003.85% down from last year.
  • Per Cytosorbents' latest filing, its Work In Process stood at $1.1 million for Q3 2025.
  • Cytosorbents' Work In Process' 5-year high stood at $1.1 million during Q3 2025, with a 5-year trough of $503000.0 in Q4 2024.
  • In the last 3 years, Cytosorbents' Work In Process had a median value of $782000.0 in 2025 and averaged $775085.4.
  • Within the past 5 years, the most significant YoY rise in Cytosorbents' Work In Process was 4003.85% (2024), while the steepest drop was 4003.85% (2024).
  • Over the past 3 years, Cytosorbents' Work In Process (Quarter) stood at $838871.0 in 2023, then crashed by 40.04% to $503000.0 in 2024, then soared by 124.65% to $1.1 million in 2025.
  • Its Work In Process was $1.1 million in Q3 2025, compared to $782000.0 in Q2 2025 and $621556.0 in Q1 2025.